دورية أكاديمية
أعرض في EDS

A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned.

التفاصيل البيبلوغرافية
العنوان: A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned.
المؤلفون: O'Connor MA; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Hawman DW; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America.; Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America., Meade-White K; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America., Leventhal S; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America., Song W; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Randall S; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; HDT Bio, Seattle, Washington, United States of America., Archer J; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; HDT Bio, Seattle, Washington, United States of America., Lewis TB; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Brown B; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Fredericks MN; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Sprouse KR; Department of Biochemistry, University of Washington, United States of America., Tunggal HC; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Maughan M; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Iwayama N; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Ahrens C; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Garrison W; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Wangari S; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Guerriero KA; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Hanley P; Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America., Lovaglio J; Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America., Saturday G; Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America., Veesler D; Department of Biochemistry, University of Washington, United States of America., Edlefsen PT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Khandhar AP; HDT Bio, Seattle, Washington, United States of America., Feldmann H; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America., Fuller DH; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Erasmus JH; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.; HDT Bio, Seattle, Washington, United States of America.
المصدر: PLoS pathogens [PLoS Pathog] 2023 Apr 19; Vol. 19 (4), pp. e1011298. Date of Electronic Publication: 2023 Apr 19 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, c2005-
مواضيع طبية MeSH: mRNA Vaccines* , COVID-19 Vaccines*/immunology, Macaca nemestrina ; Lung/immunology ; Lung/virology ; SARS-CoV-2/physiology ; Animals ; Antibodies, Neutralizing/immunology ; COVID-19/transmission
مستخلص: The global SARS-CoV-2 pandemic prompted rapid development of COVID-19 vaccines. Although several vaccines have received emergency approval through various public health agencies, the SARS-CoV-2 pandemic continues. Emergent variants of concern, waning immunity in the vaccinated, evidence that vaccines may not prevent transmission and inequity in vaccine distribution have driven continued development of vaccines against SARS-CoV-2 to address these public health needs. In this report, we evaluated a novel self-amplifying replicon RNA vaccine against SARS-CoV-2 in a pigtail macaque model of COVID-19 disease. We found that this vaccine elicited strong binding and neutralizing antibody responses against homologous virus. We also observed broad binding antibody against heterologous contemporary and ancestral strains, but neutralizing antibody responses were primarily targeted to the vaccine-homologous strain. While binding antibody responses were sustained, neutralizing antibody waned to undetectable levels in some animals after six months but were rapidly recalled and conferred protection from disease when the animals were challenged 7 months after vaccination as evident by reduced viral replication and pathology in the lower respiratory tract, reduced viral shedding in the nasal cavity and lower concentrations of pro-inflammatory cytokines in the lung. Cumulatively, our data demonstrate in pigtail macaques that a self-amplifying replicon RNA vaccine can elicit durable and protective immunity to SARS-CoV-2 infection. Furthermore, these data provide evidence that this vaccine can provide durable protective efficacy and reduce viral shedding even after neutralizing antibody responses have waned to undetectable levels.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: JHE, APK, JA, and DHF have equity interest in HDT Bio Corp. JHE and APK are inventors on granted U.S. patents pertaining to HDT Bio’s proprietary cationic nanocarrier formulation. JHE and DHF have current or previous consulting agreements with various life sciences companies. All other authors declare that they have no competing interests.
(Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
التعليقات: Update of: bioRxiv. 2022 Aug 09;:. (PMID: 35982677)
References: Lancet. 2021 Dec 18;398(10318):2258-2276. (PMID: 34863358)
Nature. 2020 Oct;586(7830):583-588. (PMID: 32731257)
EBioMedicine. 2022 Sep;83:104196. (PMID: 35932641)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Nat Med. 2022 May;28(5):1063-1071. (PMID: 35189624)
Sci Immunol. 2022 May 20;7(71):eabo1303. (PMID: 35324269)
Nat Rev Immunol. 2022 Dec 19;:. (PMID: 36536068)
Nature. 2020 Oct;586(7830):578-582. (PMID: 32731258)
Sci Adv. 2021 Mar 19;7(12):. (PMID: 33608249)
PLoS Biol. 2022 May 5;20(5):e3001609. (PMID: 35512013)
N Engl J Med. 2021 Aug 12;385(7):664-666. (PMID: 34233096)
Lancet. 2022 Feb 12;399(10325):625-626. (PMID: 35063123)
Nature. 2020 Oct;586(7830):567-571. (PMID: 32756549)
Lancet. 2021 Jul 31;398(10298):385-387. (PMID: 34274038)
Cell. 2022 Jan 6;185(1):113-130.e15. (PMID: 34921774)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Cell. 2021 Jun 24;184(13):3467-3473.e11. (PMID: 34133941)
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684. (PMID: 33251966)
EBioMedicine. 2022 Aug;82:104158. (PMID: 35834885)
J Infect Dis. 2022 May 16;225(10):1688-1693. (PMID: 35323975)
Sci Transl Med. 2020 Aug 5;12(555):. (PMID: 32690628)
Mol Ther Methods Clin Dev. 2020 Jun 18;18:402-414. (PMID: 32695842)
Nature. 2021 Feb;590(7847):630-634. (PMID: 33276369)
Front Immunol. 2022 Jan 14;12:808932. (PMID: 35095897)
Nat Med. 2021 Nov;27(11):2025-2031. (PMID: 34526698)
Science. 2022 Jan 07;375(6576):43-50. (PMID: 34812653)
Nat Commun. 2021 Oct 7;12(1):5868. (PMID: 34620866)
N Engl J Med. 2021 Jun 10;384(23):2259-2261. (PMID: 33822494)
N Engl J Med. 2021 Dec 16;385(25):2348-2360. (PMID: 34587382)
Nature. 2021 Aug;596(7871):276-280. (PMID: 34237773)
Science. 2020 Dec 4;370(6521):1227-1230. (PMID: 33115920)
Science. 2021 Sep 17;373(6561):eabj0299. (PMID: 34529476)
Sci Transl Med. 2021 Aug 11;13(606):. (PMID: 34285130)
Front Immunol. 2021 Aug 20;12:681516. (PMID: 34489933)
Cell. 2020 Oct 1;183(1):169-184.e13. (PMID: 32931734)
Cell. 2022 Apr 28;185(9):1549-1555.e11. (PMID: 35427477)
PLoS Pathog. 2021 Apr 26;17(4):e1009509. (PMID: 33901246)
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657. (PMID: 34245907)
N Engl J Med. 2021 Aug 12;385(7):585-594. (PMID: 34289274)
Vet Pathol. 2022 Jul;59(4):673-680. (PMID: 34963391)
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169. (PMID: 34437521)
Nature. 2021 Apr;592(7853):283-289. (PMID: 33524990)
Science. 2022 Feb 11;375(6581):678-680. (PMID: 35040667)
Nat Commun. 2021 Feb 8;12(1):844. (PMID: 33558507)
EBioMedicine. 2022 Aug;82:104188. (PMID: 35907368)
Nat Immunol. 2020 Oct;21(10):1146-1151. (PMID: 32855555)
J Infect Dis. 2021 Feb 3;223(2):197-205. (PMID: 33535236)
N Engl J Med. 2021 Jan 7;384(1):80-82. (PMID: 33270381)
Elife. 2022 Feb 22;11:. (PMID: 35191378)
Am J Trop Med Hyg. 2021 Apr 20;104(6):2195-2198. (PMID: 33878029)
معلومات مُعتمدة: K01 MH123258 United States MH NIMH NIH HHS; P51 OD010425 United States OD NIH HHS; U42 OD011123 United States OD NIH HHS
المشرفين على المادة: 0 (mRNA Vaccines)
0 (COVID-19 Vaccines)
0 (Antibodies, Neutralizing)
تواريخ الأحداث: Date Created: 20230419 Date Completed: 20240129 Latest Revision: 20240411
رمز التحديث: 20240411
مُعرف محوري في PubMed: PMC10150980
DOI: 10.1371/journal.ppat.1011298
PMID: 37075079
قاعدة البيانات: MEDLINE
الوصف
تدمد:1553-7374
DOI:10.1371/journal.ppat.1011298